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Colorectal cancer (CRC) is a major public health issue worldwide, and
novel tumor markers may contribute to its efﬁcient management by helping
in early detection, prognosis or surveillance of disease. The aim of our
study was to identify new serum biomarkers for CRC, and we followed a
phased biomarker discovery and validation process to obtain an accurate
preliminary assessment of potential clinical utility. We compared colonic
tumors and matched normal tissue from 15 CRC patients, using two-
dimensional difference gel electrophoresis (2D-DIGE), and identiﬁed 17
proteins that had signiﬁcant differential expression. These results were fur-
ther conﬁrmed by western blotting for heat shock protein (HSP) 60, gluta-
thione-S-transferase Pi, a-enolase, T-complex protein 1 subunit b, and
leukocyte elastase inhibitor, and by immunohistochemistry for HSP60.
Using mAbs raised against HSP60, we developed a reliable (precision of
5–15%) and sensitive (0.3 ngÆmL
)1) immunoassay for the detection of
HSP60 in serum. Elevated levels of HSP60 were found in serum from CRC
patients in two independent cohorts; the receiver-operating characteristic
curve obtained in 112 patients with CRC and 90 healthy controls had an
area under the curve (AUC) of 0.70, which was identical to the AUC of
carcinoembryonic antigen. Combination of serum markers improved clini-
cal performance: the AUC of a three-marker logistic regression model com-
bining HSP60, carcinoembryonic antigen and carbohydrate antigen 19-9
reached 0.77. Serum HSP60 appeared to be more speciﬁc for late-stage
CRC; therefore, future studies should evaluate its utility for determining
prognosis or monitoring therapy rather than early detection.
Abbreviations
AUC, area under the curve; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, conﬁdence interval;
CK19, cytokeratin 19; CRC, colorectal cancer; CV, coefﬁcient of variation; 2D-DIGE, two-dimensional difference gel electrophoresis;
GST-Pi, glutathione-S-transferase Pi; HSP, heat shock protein; IHC, immunohistochemistry; IPG, immobilized pH gradient; LEI, leukocyte
elastase inhibitor; LLOQ, lower limit of quantiﬁcation; LOB, limit of blank; LOD, limit of detection; PGAM1, phosphoglycerate mutase 1;
RE, relative error; SD, standard deviation; TCP1b, T-complex protein 1 subunit b; TMA, tissue microarray.
FEBS Journal 278 (2011) 4845–4859 ª 2011 bioMe ´rieux Journal compilation ª 2011 FEBS 4845Introduction
With an incidence of more than 1.2 million new cases
and 600 000 deaths per year, colorectal cancer (CRC)
is a major public health issue worldwide [1]. Currently,
mass screening relies principally on fecal occult blood
tests [2,3], and the reference standard for diagnosis
conﬁrmation is colonoscopy, an invasive method that
causes major morbidity in 0.3% of subjects [4,5]. Diag-
nosis and treatment of CRC at an early stage of cancer
development considerably improves the chances of sur-
vival; patients diagnosed at an advanced stage have a
rather poor prognosis. In fact, disease stage at the time
of diagnosis is still the main prognostic factor for
CRC.
Surgical resection is the recommended treatment for
most CRC patients; stage III patients will receive adju-
vant chemotherapy following surgery, which improves
survival probability at 5 years [6]. The utility of adju-
vant chemotherapy in stage II patients is still subject
to debate, and its use in this population is not recom-
mended, although there is clear evidence that it would
be helpful for a subgroup of patients with stage II dis-
ease [7]. One of the important needs in CRC manage-
ment is the identiﬁcation of stage II patients who may
beneﬁt from adjuvant chemotherapy. Up to 40–50%
of CRC patients will develop advanced disease over
time, despite treatment efforts [8]. Another clinical
need is the surveillance of patients following comple-
tion of therapy, in order to detect recurrence of disease
as early as possible. Monitoring therapy in advanced
disease is also beneﬁcial [9].
Carcinoembryonic antigen (CEA) was one of the
ﬁrst serological tumor markers to be discovered, and
has contributed signiﬁcantly to the acceptance of
tumor markers as aids in making clinical decisions.
Today, after 30 years of clinical research, it is well
established that CEA should not be used for screening
or early detection of CRC, and that it has some utility
for determining prognosis as well as monitoring
advanced disease, in association with clinical history.
The unique clinical indication in which CEA is consen-
sually recommended by different expert groups is post-
operative surveillance; there is solid cumulative
evidence demonstrating its utility for this speciﬁc
purpose [9,10].
Several other serum markers, such as carbohydrate
antigen 19-9 (CA19-9), carbohydrate antigen 242 and
tissue inhibitor of metalloproteinases type 1, have been
developed, and are being evaluated for various clinical
uses in CRC management (reviewed in [9]). Regretta-
bly, none has the required diagnostic performance to
be considered for screening or early detection
purposes. These serum markers may contribute to
determining prognosis or monitoring therapy, but
high-powered, controlled studies are still needed to
assess their added value. Therefore, there is a need for
new CRC biomarkers that will satisfactorily meet one
or several of the clinical needs discussed above. Serum
markers are preferred over tissue or stool-based assays,
especially for screening and monitoring purposes,
which require repeat testing. Blood-based tests have
better acceptance and provide increased patient com-
pliance.
The aim of our study was to identify such candidate
protein markers and investigate their possible clinical
use. We used a proteomics strategy relying on 2D-gel-
based discovery in tissue and further conﬁrmation of
potential candidates in serum. Recent examples in the
literature show that similar approaches can successfully
yield novel serum biomarkers for CRC, such as nico-
tinamide-N-methyltransferase [11], proteasome activa-
tor complex subunit [12], S100A8, and S100A9 [13,14].
To date, none of these tumor markers has been com-
pletely clinically evaluated and has shown utility.
Given the diversity of clinical needs in CRC manage-
ment, the small number of candidate serum biomar-
kers, and the low success rate of clinical utility
assessments, it is necessary to identify novel, additional
tumor markers and to determine the clinical indica-
tions in which they may have an added value. We
compared colonic tumors and matched normal mucosa
from CRC patients, using 2D difference gel electro-
phoresis (2D-DIGE), and identiﬁed 17 proteins that
had signiﬁcant differential abundance. Among them,
heat shock protein (HSP) 60 was reported to be
actively secreted by tumor cells [15], and its expression
in tissue was correlated with tumor grade and progres-
sion [16,17]. Thus, it appeared to be the best candidate
for evaluation as a potential serum marker for CRC.
We followed the multistep biomarker discovery and
validation process proposed by Rifai et al., which
involves candidate discovery, qualiﬁcation, veriﬁcation,
assay optimization and biomarker validation phases
[18]. Our results are reported using the terminology
proposed in this process. Using a well-characterized
and robust research immunoassay speciﬁcally designed
for the detection of HSP60 in serum, we successfully
completed the veriﬁcation phase, and were able to
show, for the ﬁrst time, that HSP60 levels are more
frequently increased in the serum of CRC patients
than in healthy controls. Serum HSP60 seemed to be
more speciﬁc for late-stage cancer, so it might be better
suited for disease monitoring than for early detection.
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Identiﬁcation of differentially expressed proteins
with 2D-DIGE
Colonic tumor and matched normal mucosa were
obtained from 15 patients undergoing surgical resec-
tion (Table 1). Epithelial cells were puriﬁed from each
tissue specimen, and total protein extracts were pre-
pared. For each patient, expression was compared
between protein extracts of tumor and normal epithe-
lial cells with 2D-DIGE analysis, including a dye swap
replicate between Cy3 and Cy5 to avoid labeling bias
[19,20]. The internal standard was a cytoplasmic pro-
tein extract from Caco-2 cells labeled with Cy2 dye. A
total of 30 well-resolved gels (two for each patient)
were obtained, and on each gel  800 protein spots
were detected in a pI range of 5–8 (Fig. 1). After back-
ground subtraction, in-gel normalization, and removal
of artefact spots, the matching rate of each internal
standard gel and the master gel (Cy2) reached over
90%. Following matching, image analysis was carried
out to compare the median ratio of protein abundance
between paired colon tumor tissues and adjacent nor-
mal mucosa in the 2D-DIGE maps (Fig. 2A). Relative
protein expression, which corresponds to log2-trans-
formed, normalized spot volumes, is shown in Fig. 2B
for some selected spots. Protein spots that were above
the 1.5-fold-change threshold were tested for statistical
signiﬁcance. Among 17 spots that were determined to
be signiﬁcantly different between tumor and normal
colon mucosa, 16 were upregulated in adenocarcinoma
and one was downregulated (Fig. 1; Table 2).
MS identiﬁcation of protein spots was carried out
by using replicate gels with 1 mg of protein extract
from cancer and normal tissues, in order to compen-
sate for the low abundance of some proteins and cir-
cumvent the impact of dyes on MS identiﬁcation.
After matching with 2D-DIGE images using image-
master software (GE Healthcare, Velizy Villacoublay,
France), the protein spots were localized on the repli-
cate gels and excised. The peptides produced by tryptic
digestion of spots were analyzed by MALDI-TOF MS,
and all proteins were successfully identiﬁed by peptide
mass ﬁngerprinting (Table 2).
Among them, aminoacylase-1, pre-mRNA-processing
factor 19, T-complex protein 1 subunit a and T-com-
plex protein 1 subunit b (TCP1b) are reported for the
ﬁrst time to be differentially expressed between tumor
and normal colon mucosa. This points to the fact that
the differential expression proﬁle of CRC tissue has still
not been fully characterized, despite the growing num-
ber of proteomic analyses. However, our data also
include several proteins that were reported in previous
publications, such as a-enolase [11,13,21–23], tropomy-
osin b-chain [24–26], and HSP60 [21,23,27]. This indi-
cates that our 2D-DIGE analysis was accurate and in
concordance with prior studies. After the identiﬁcation
of potentially interesting tissue markers, it was neces-
sary to go further, ﬁrst conﬁrming differential expres-
sion with independent techniques, and then extending
observations made in tissue to serum. These are the
steps called marker qualiﬁcation by Rifai et al. [18].
Marker qualiﬁcation
To conﬁrm the differential expression results obtained
by 2D-DIGE analysis, western blot was carried out for
eight proteins among 17, with tissue samples from
eight independent patients (Table 1; Fig. 2C). HSP60,
glutathione-S-transferase pi (GST-Pi), a-enolase, TCP1b
and cytokeratin 19 (CK19) were detected in the large
majority of the samples, and signiﬁcant overexpression
in tumor tissue as compared with matching normal
mucosa was conﬁrmed for the ﬁrst four proteins, but
Table 1. Clinical data of colon cancer patients used in 2D-DIGE
and western blot analyses. UICC, Union for International Cancer
Control.
Patient no.
Age
(years) Sex
Global
staging
(UICC)
Tumor
localization
TNM
staging
2D-DIGE
1 84 F III Right colon T4N2M0
2 71 F III Sigmoid T3N1M0
3 61 M III Right colon T3N2M0
4 75 M II Left colon T3N0M0
5 73 M II Left colon T3N0M0
6 73 M II Right colon T3N0M0
7 57 M II Right colon T3N0M0
8 71 M II Right colon T3N0M0
9 73 M III Left colon T3N1M0
10 79 M II Left colon T3N0M0
11 61 M IV Left colon T2N0M1
12 88 F II Right colon T3N0M0
13 65 F III Left colon T1N1M0
14 79 M III Sigmoid T3N2M0
15 78 M III Right colon T3N1M0
Western blot
1 82 M II Left colon T4N0M0
2 76 M IV Right colon T4N2M1
3 72 M IV Right colon T4N1M1
4 62 M IV Left colon T3N1M1
5 79 F II Right colon T3N0M0
6 59 M III Transverse
colon
T3N1M0
7 77 M IV Right colon T3N0M1
8 73 M IV Left colon T2N0M1
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(PGAM1) and HSP90b, the overall signal level was
low, so it was difﬁcult to draw conclusions. Leukocyte
elastase inhibitor (LEI) was detected in only four of
eight patients, but when detected it was consistently
less abundant in colon carcinoma than in normal tis-
sue, in agreement with our 2D-DIGE results but in
contrast to published data [28]. Taken these ﬁndings
together, there was good concordance between western
blot data and 2D-DIGE results.
The aim of our study was to identify a serological
candidate biomarker for CRC, as blood-based tests are
easier to implement in routine clinical practice. Among
potential CRC markers conﬁrmed by western blot,
HSP60 had the ability to reach the bloodstream. It is
actively secreted by tumor cells [15], and has been found
in plasma of individuals with cardiovascular disease risk
[29,30]. Moreover, HSP60 was identiﬁed as one of the
proteins with the highest fold change ratio (3.25,
P < 0.0001) in 2D-DIGE between colonic tumors and
matching normal mucosa. For all of these reasons, we
focused on HSP60 for marker qualiﬁcation in serum.
Conﬁrmation of HSP60 overexpression in colonic
adenocarcinoma by immunohistochemistry (IHC)
Immunohistochemical analysis was performed to con-
trol the mAbs against HSP60 selected for immunoas-
say development and to check their immunoreactivity
proﬁles. The additional aim of IHC was to further
conﬁrm 2D-DIGE data with another independent tech-
nique. To this end, 20 independent colon cancer tissue
specimens were selected from archived formalin-ﬁxed,
parafﬁn-embedded tissue blocks. Clinical and patho-
logical data of corresponding patients are shown in
Table 3. For each patient, matched tissue samples cor-
responding to the tumor center, tumor just behind the
invasion front and adjacent normal mucosa were ana-
lyzed. Representative immunohistochemical images
obtained with the mAb 11D5E10 are shown in
Fig. 3A. As expected, HSP60 immunostaining was
mainly cytoplasmic in epithelial cells [16,31]. It had a
particulate appearance, consistent with mitochondrial
localization. Many of the normal colonic mucosa spec-
imens had no staining, and some exhibited weak posi-
tive reactivity to HSP60, whereas CRC tissues showed
moderate to strong reactivity. Overall, HSP60 intensity
was signiﬁcantly stronger in the invasive front
(1.7 ± 0.5, P = 0.0006) and tumor center (1.5 ± 0.7,
P = 0.0045) than in normal mucosa (0.7 ± 0.6)
(Fig. 3B). Very similar results were also obtained with
mAb 16F11D12 (data not shown), suggesting that
both antibodies are suitable for immunoassay develop-
ment. Moreover, these results conﬁrm overexpression
of HSP60 in CRC tissue, in agreement with our
2D-DIGE and western blot data, as well as with pub-
lished IHC series that analyzed HSP60 expression in
CRC tissue [32,33].
Analytical method validation for HSP60 ELISA on
VIDAS
To compare HSP60 levels in sera of CRC patients and
healthy individuals, we set up a prototype HSP60
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Fig. 1. Representative 2D-DIGE maps of colonic tissue (patient 6). Soluble proteins extracted from colon tumor (Cy5) and matched normal
tissue (Cy3) were labeled with the indicated dyes, mixed with Cy2-labeled internal standard, and subjected to IEF on pH 5-8 IPG strips. Pro-
tein samples were then separated on large-format 7.7–16.5% gradient SDS⁄PAGE gels. Molecular mass separation is 150–10 kDa (top to
bottom). Numbered spots indicate proteins that have statistically signiﬁcant differential expression between tumor tissue and adjacent nor-
mal mucosa (fold-change over 1.5 and P < 0.05 with Wilcoxon signed-rank test). MALDI-TOF MS identiﬁcation results for these spots are
shown in Table 2.
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platform, using mAbs 11E5D10 and 16F11D12. Before
moving to the next phase of our study, which was
marker qualiﬁcation in serum [18], a preliminary and
partial analytical evaluation of the HSP60 ELISA
prototype was carried out. Aspects of the clinical per-
formance of a biomarker, such as sensitivity and speci-
ﬁcity, are also impacted by the analytical performance
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Fig. 2. Western blot qualiﬁcation of differentially expressed protein spots. (A) 2D-DIGE image and corresponding 3D simulation of the
HSP60 spot in a matched tissue sample. N, normal tissue; T, tumoral tissue. (B) Relative expression of HSP60, GST-Pi, TCP1b, CK19 and
HSP90b in paired CRC samples analyzed by 2D-DIGE. Relative expression corresponds to the spot volume determined with IMAGEMASTER
2D-PLATINIUM software, transformed into logarithm base 2, and normalized with the corresponding spot volume of the internal standard image
(Cy2). Comparisons were performed with the Wilcoxon signed-rank test. (C) Western blot analysis of protein expression in eight independent
tissue sample pairs. Tubulin was used as loading control.
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quently, it is of utmost importance to use validated
methods in order to generate robust and reproducible
data. Method evaluation protocols were simpliﬁed
from the cognate Clinical and Laboratory Standards
Institute guidelines, mainly by lowering the number of
repeat measurements.
To establish the calibration model, seven nonzero
standard points spanning an assay range of 0.5–
20 ngÆmL
)1 were used. These calibrator points were
assayed in duplicate in ﬁve consecutive runs, and the
concentration–signal relationship was modeled with the
four-parameter logistic function. The goodness of ﬁt
for repeated standard curves was analyzed by using r
2,
and was equal to 0.999, indicating a nearly perfect cor-
relation. The appropriateness of the model was evalu-
ated by calculating the percentage of relative error
(RE) for back-calculated calibrator points (Table 4).
The absolute values of RE were between 0.2% and
11.2%. The coefﬁcients of variation (CVs) of calibrator
point replicates were between 4.4% and 10.3%. As
both of these acceptability criteria were lower than the
recommended limit of 15% [34], the calibration model
was deemed to be acceptable. Assay precision was
assessed with six CRC serum samples that had low,
medium and high HSP60 levels. For reproducibility
(total precision), %CV varied between 4.8% and
15.6%. As expected, within-run precision was the main
contributory factor to total variability (Table 5).
The limit of blank (LOB) was determined on 42 rep-
licate measurements of a blank serum sample. The
LOB is the 95th percentile of the distribution of
Table 2. Identiﬁcation of proteins with differential expression in colon cancer by MALDI-TOF MS. Accession number in SWISS-PROT pro-
tein database. Spot number reported in Fig. 1. n, number of patient samples in which the spot was identiﬁed. Fold-change ratio: a positive
ratio indicates increased abundance in colon carcinoma, and a negative ratio indicates a decrease. P-value of Wilcoxon test applied to n
paired 2D-DIGE analysis results. Protein score: amino acid sequence coverage. Previous report: previously reported as differential expression
in CRC (normal versus tumor); M indicates that the difference was observed between metastatic and nonmetastatic colon cancer; + or )
signs are used when there is controversy, and indicate the differential expression that was reported in the associated study.
Recommended name
Accession
number
Spot
number
Molecular
mass
(kDa) pI n
Fold-
change
ratio P-value
Protein
score
Sequence
coverage
(%)
Previous
report
60-kDa heat shock protein,
mitochondrial
P10809 1 61.1 5.6 15 3.25 < 0.0001 267 57.1 21,23,27
78-kDa glucose-regulated protein P11021 2 72.3 4.9 15 1.60 0.028 301 47.4 [27] )
Actin, cytoplasmic 1 P60709 3 41.7 5.5 8 3.96 < 0.0001 229 60.8 21,27
a-Enolase P06733 4 47.2 7.7 8 1.59 0.002 259 62.1 11,13,21–23
Aminoacylase-1 Q03154 5 45.9 5.7 15 1.78 0.003 228 40.7
Heat shock protein 90b P08238 6 83.3 4.8 8 1.59 0.008 183 47.6 [42] M
Keratin, type I cytoskeletal 19 P08727 7 44.1 4.9 8 1.54 0.009 186 45.5 21
Leukocyte elastase inhibitor P30740 8 42.7 5.9 11 )2.26 0.006 250 50.9 [28] +
Peroxiredoxin-2 P32119 9 21.9 5.6 15 1.67 0.041 164 68.7
Phosphoglycerate mutase 1 P18669 10 28.8 6.8 15 2.82 0.002 159 70.8 [23] ), [27] +,
[42] +
Pre-mRNA-processing factor 19 Q9UMS4 11 55.2 6.0 15 1.71 0.0001 129 44.6
Protein S100-A8 P05109 12 10.8 6.6 15 2.01 < 0.0001 148 81.7 13
T-complex protein 1 subunit a P17987 13 60.3 5.7 15 2.45 0.040 71 13.7
T-complex protein 1 subunit b P78371 14 57.5 5.3 15 1.71 0.0001 145 34.8
Tropomyosin b-chain P07951 15 32.9 4.5 8 1.79 0.0002 77 34.2 [25,26] M
Elongation factor 1c P26641 16 50.0 6.3 11 1.85 0.008 213 43.8 28
Glutathione-S-transferase Pi P09211 17 23.2 5.3 15 1.53 0.0004 239 62.2 [26] M, [28]
Table 3. Clinical data of colon cancer patients used in IHC analysis.
UICC, Union for International Cancer Control.
n %
Sex
Male 10 50
Female 10 50
Tumor localization
Right colon 7 35
Left colon 7 35
Transverse colon 3 15
Sigmoid 3 15
Global staging (UICC)
I1 5
II 5 25
III 12 60
IV 2 10
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was 0.12 ngÆmL
)1. The limit of detection (LOD) is the
lowest concentration of the biomarker that the
designed assay can reliably differentiate from the back-
ground noise. Four replicates of four serum samples,
with HSP60 levels between LOB and four-fold LOB,
were tested for 3 days. The LOD was 0.30 ngÆmL
)1.
Two of the samples previously used for LOD determi-
nation were tested again in four replicates in two inde-
pendent runs, in order to assess the lower limit of
quantiﬁcation (LLOQ). The LLOQ is the lowest con-
centration that can be measured with acceptable accu-
racy and precision. The LLOQ was 0.30 ngÆmL
)1, like
the LOD. All of these analyses show the satisfactory
analytical performances of our prototype and guaran-
tee the quality and reproducibility of results obtained
using this assay.
Qualiﬁcation and veriﬁcation of HSP60 as a
serum biomarker of CRC
The qualiﬁcation cohort (cohort I) comprised 40 CRC
patients and 40 healthy individuals; their clinical data
are presented in Table 6. Mean HSP60 levels measured
by ELISA in these control and cancer sera were
0.1 ± 0.1 and 2.0 ± 0.6 ngÆmL
)1, respectively. This
increase in HSP60 levels in CRC patients was statisti-
cally signiﬁcant (P = 0.0001; Fig. 4), indicating that
HSP60 is a potential serum biomarker for CRC.
To verify the increase in HSP60 serum levels observed
in CRC patients, a second and independent cohort of 90
healthy donors and 112 CRC patients was assayed
(cohort II). This veriﬁcation cohort was designed so that
each clinical stage of the disease was equally represented
among the CRC patients (Table 6). Again, serum
A
B
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Ctr
Fig. 3. (A) Representative immunohistochemical staining images of
HSP60 in normal colonic mucosa, tumor center, and tumor just
behind the invasive front; magniﬁcation, · 20. For negative controls
(bottom panels, Ctr), primary antibody against HSP60 was replaced
by an irrelevant mouse IgG. (B) Comparison of HSP60 staining
scores between matched normal mucosa, invasive front and tumor
center in a series of 20 specimens from CRC patients. Analysis of
variance with Friedman’s test showed signiﬁcant differences in the
dataset (P < 0.0001). Pairwise post hoc comparisons were per-
formed with Dunn’s multiple comparison test, and the correspond-
ing P-values are shown.
Table 4. %REs and %CVs of back-calculated standard curve val-
ues of HSP60 ELISA assay.
Calibrator point A B C D E F G
Nominal value
(ngÆmL
)1)
0.5 1.0 2.5 5.0 7.5 10.0 20.0
Mean back-calculated
value (ngÆmL
)1)
0.6 1.0 2.5 4.9 7.4 10.2 20.0
%RE 11.2 2.3 0.4 1.2 1.4 1.6 0.2
%CV 10.3 5.8 4.7 6.7 5.8 4.4 4.4
Table 5. HSP60 ELISA assay precision.
Sample QC1 QC2 QC3 QC4 QC5 QC6
Mean dose (ngÆmL
)1) 0.6 2.3 4.4 8.8 13.8 20.2
%CV intra-assay 13.3 5.9 3.3 7.2 5.3 4.4
% Variation part
a 73 83 44 57 88 86
%CV inter-assay
b 15.6 6.4 5.0 9.5 5.6 4.8
aPercentage of total variability attributable to intra-assay precision.
bTotal variability, all assessed sources (intra-assay, run, day, instru-
ment). QC: quality control sample.
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(1.3 ± 0.3 ngÆmL
)1; range, 0–25 ngÆmL
)1) than in
healthy volunteers (0.2 ± 0.1 ngÆmL
)1; range, 0–1.7
ngÆmL
)1)( P < 0.0001) (Fig. 5A), conﬁrming the obser-
vation made on the ﬁrst cohort. Among CRC patients,
only 38% had an HSP60 level < 0.30 ngÆmL
)1, which is
the lower limit of quantiﬁcation, as compared with 70%
for healthy controls. Given the concordant results in
two independent cohorts and the robust analytical
performance of our HSP60 ELISA assay on VIDAS, we
can conﬁdently conclude that serum HSP60 levels are
more frequently increased in CRC patients than in
healthy controls.
The clinical performance of serum HSP60 as a bio-
marker to discriminate between cancer and noncancer
patients was assessed with receiver-operating character-
istic curve analysis. The area under the curve (AUC)
represents an average of the sensitivity over all possible
speciﬁcities. For the veriﬁcation cohort (n = 202), the
AUC was 0.70 [95% conﬁdence interval (CI) 0.63–
0.77]. When the speciﬁcity was set at 90%, the sensitiv-
ity of HSP60 was 40%.
We also analyzed whether serum HSP60 levels were
increased at all clinical stages of disease. Figure 5B
shows that this rise was mainly observed in patients
with stage IV cancer, the mean level in this group
reaching 3.5 ± 1.0 ngÆmL
)1. Moreover, samples below
the limit of quantiﬁcation were less frequent in this
group (26%). These results imply that HSP60 is a
serum marker for advanced stages of disease, and that
it may not be well suited for early detection.
Comparison and combination of HSP60 with
current serum biomarkers of CRC
Serum CEA and CA19-9 are used in clinical practice
for CRC patient monitoring, and contribute to diagno-
sis. CEA and CA19-9 levels were tested in the veriﬁca-
tion cohort with commercial assays. As expected, CEA
levels were signiﬁcantly higher in CRC patients
(104 ± 52 ngÆmL
)1) than in healthy volunteers
(1.1 ± 0.1 ngÆmL
)1)( P < 0.0001) (Fig. 5C). CA19-9
levels were also signiﬁcantly higher in CRC patients
(5592 ± 3359 UÆmL
)1) than in healthy volunteers
(4.5 ± 0.8 UÆmL
)1)( P = 0.0003) (Fig. 5D). The AUC
values were 0.70 (95% CI 0.62–0.78) and 0.65
(95% CI 0.57–0.73) for CEA and CA19-9, respectively.
When the speciﬁcity was set at 90%, the sensitivities of
CEA and CA19-9 assays reached 41% and 36%,
respectively. These results indicate that the diagnostic
performance of serum HSP60 for cancer⁄no cancer dis-
crimination is very similar to that of CEA and better
than that of CA19-9. Consequently, with the current
assay format, HSP60 alone would be of limited clinical
utility for the diagnosis of CRC, like CEA or CA19-9.
Combined use of markers can often improve clinical
performance, as the types of biological information
provided by the different markers do not totally over-
lap. We performed logistic regression to establish a
mathematical model that combines HSP60, CEA, and
CA19-9. Its output is expressed in arbitrary units; as
expected, values in CRC patients were signiﬁcantly
higher than in healthy volunteers (P < 0.0001)
(Fig. 5E). The AUC of the model reached 0.77
(95% CI 0.70–0.84) (Fig. 5F), showing a signiﬁcant
7% improvement over the performances of individual
Table 6. Clinical data of CRC patients and controls assayed by
ELISA. UICC, Union for International Cancer Control.
Cohort I Cohort II
Age (years)
Control 55 ± 5 58 ± 4
Cancer 71 ± 11 70 ± 11
Sex, male⁄female, no. (%)
Control 27 (68)⁄13 (32) 54 (60)⁄36(40)
Cancer 25 (63)⁄15 (38) 61 (54)⁄51(46)
Tumor localization, no. (%)
Right colon 10 (25) 40 (36)
Left colon 9 (23) 40 (36)
Transverse colon 1 (3) 6 (5)
Sigmoid 3 (8) 15 (13)
Rectum 17 (43) 11 (10)
Global staging (UICC), no. (%)
I 8 (20) 27 (24)
II 8 (20) 29 (26)
III 15 (38) 29 (26)
IV 9 (23) 27 (24)
Fig. 4. Serum levels of HSP60 in the qualiﬁcation cohort, 40
healthy controls and 40 CRC patients, measured by ELISA. Serum
HSP60 levels were signiﬁcantly elevated in CRC patients
(P = 0.0001, one-tailed Mann–Whitney test). The gray line repre-
sents the mean HSP60 concentration for the CRC group.
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90%, the sensitivity of the three-marker combination
increased to 47%. When the speciﬁcity was set as high
as 98%, to be comparable with the reference standard
fecal occult blood test assay Hemoccult II, the three-
marker combination reached a sensitivity of 36%, in
the range of sensitivity of Hemoccult II for cancer (25–
38%) [35], but not better. However, the utility of this
three-marker combination should be further evaluated
for monitoring purposes, as it may represent an
improvement over CEA or CA19-9 alone.
Discussion
The aim of our study was to identify and verify new
serum markers of CRC, as well as to generate data
that will allow the best-suited clinical use to be chosen.
To circumvent the well-known difﬁculties associated
with direct protein biomarker discovery in serum [18],
we carried out a comparison of protein expression lev-
els, using 2D-DIGE, in paired tumor tissue and match-
ing normal mucosa samples. 2D-gel electrophoresis
analyses are often used on protein extracts from crude
Fig. 5. Serum levels of HSP60 and other CRC markers in the veriﬁcation cohort. (A) HSP60, n=202, AUC = 0.70. (C) CEA, n = 175,
AUC = 0.70. (D) CA19-9, n = 175, AUC = 0.65. (E) Three-marker combination calculated with a logistic regression model, expressed in arbi-
trary units, n = 175. Mean marker concentrations are represented by lines. Control and cancer groups were compared by use of the one-
tailed Mann–Whitney test. (F) Receiver-operating characteristic curve of the three-marker combination, AUC = 0.77. (B) HSP60 concentration
according to CRC stage (I–IV). Data are means ± standard errors. Analysis of variance with Friedman’s test indicated signiﬁcant differences
in HSP60 levels between groups (P < 0.0001). Pairwise comparisons were performed with Dunn’s multiple comparison test, and the corre-
sponding P-values are shown.
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and an enrichment step that allows partial or total
puriﬁcation of tumor cell populations from surround-
ing undesired cells may increase the signiﬁcance of dif-
ferential analysis results. Various methods can be used
to achieve this, such as macrodissection [13], or laser
capture microdissection, which is much more powerful
but requires speciﬁc equipment [36]. As CRC is an
adenocarcinoma, we isolated the epithelial cell popula-
tion by using a kit based on magnetic beads coated
with an antibody that recognizes two membrane anti-
gens expressed on most normal and neoplastic human
epithelial cells [37]. This easy method works well; no
contaminant proteins, such as serum albumin, sero-
transferrin, or apolipoprotein AI, were found in our
differential analysis. Among 800 protein spots present
in our 2D-DIGE gels, we identiﬁed only 17 as being
different between tumor and normal epithelial cells.
This is comparable with other studies that analyzed
pairs of CRC and normal tissue using 2D electropho-
resis coupled to MS [13,21,22,25,28,38–40]: the number
of proteins reported to be differentially expressed ran-
ged from nine [40] to 52 [28]. For studies relying on
the 2D-DIGE technique, this number was often higher
than 30 [13,21,28], probably because of the gain in
reproducibility resulting from the use of ﬂuorescent
dyes over more traditional, silver nitrate staining meth-
ods. In comparison, the number of differentially
expressed proteins that we have found is lower. We
suggest that this is because we analyzed puriﬁed cell
populations rather than bulk tissue.
In this study, we identiﬁed 17 proteins as showing
substantial differences between tumor and normal
colon tissues. Differential expression of aminoacylase-
1, pre-mRNA-processing factor 19, T-complex pro-
tein 1 subunit a and TCP1b has been, to our
knowledge, shown for the ﬁrst time (Table 2). Our
data also included proteins reported in previous
proteomic studies, such as a-enolase [11,13,22,23,41],
tropomyosin b-chain [24–26], cytoplasmic actin 1
[21,27], GST-Pi [26,28], and HSP60 [21,23,27]. For
these candidate biomarkers, our results were in
agreement with published data. LEI (SERPINB1)
was downregulated in tumor tissues, as shown by
2D-DIGE and further conﬁrmed by western blot,
unlike what has been reported by others [28]. This lat-
ter technique also showed that LEI was detected only
in half of the patients (four of eight); the other half
did not express LEI at all, at least not at levels that
can be detected by western blot. This heterogeneity in
expression levels could account for the contradictory
results that are reported. For GST-Pi and TCP1b,
there was good concordance between 2D-DIGE results
and western blot; these proteins were frequently
detected in our experiments in colon tissue, and should
be further evaluated as tumor markers. For PGAM1
and HSP90b, although there was concordance between
2D-DIGE and western blot data, the tissue levels of
these proteins were at the lower detection limit of both
techniques, and more sensitive techniques, such as
IHC, could be more suited for marker qualiﬁcation.
Finally, our proteomic data also indicate that S100A8
protein is more abundant in colonic tumors than in
matched normal tissue, in agreement with 2D-DIGE
data reported recently by Kim et al. [13]. Strikingly,
we did not identify S100A9 as a differentially
expressed protein, although it has been reported much
more frequently than S100A8 [13,23,28,42]. Moreover,
the study by Kim et al. [13] also showed that the levels
of both S100A8 and S100A9 are increased in plasma
of CRC patients, indicating that they could be interest-
ing serological markers for CRC.
As the number of studies dealing with the differen-
tial expression proﬁles of CRC tissue increases, a large
collection of potential candidate markers are becoming
available. Nevertheless, each study brings its own dis-
crepancies, resulting from methodological differences
in sample collection, processing, or analysis, and from
variations in genetic or pathological characteristics of
the patients enrolled. To generate reliable data that
will lead to the validation and clinical use of new bio-
markers, it is necessary not only to conﬁrm observa-
tions with independent techniques, but also to work on
well-characterized patient samples and increase the
number of patients included in the analyses. For these
reasons, we used four different protein detection tech-
niques and patient cohorts from four different sources
in our study.
For the next phases of biomarker discovery and vali-
dation, which are marker qualiﬁcation in serum and
further veriﬁcation [18], we uniquely focused on
HSP60 in our study. Both our results and data from
the literature suggest that it has the potential to be a
serum biomarker, in addition to being a tissue biomar-
ker [32]. Indeed, HSP60 is actively secreted by tumor
cells, most probably through the exosomal pathway
[15], and titers of antibodies against HSP60 were
reported to be higher in CRC patients than in controls
[43]. None of the commercial HSP60 assays that we
evaluated had a satisfactory precision and detection
limit in serum; and we therefore set up an in-house
assay method. With %CVs for total precision in the
range of 5–15%, our HSP60 assay was extremely reli-
able for the detection of serum HSP60, and allowed us
to show clearly that HSP60 itself was a serum marker
for CRC in two independent cohorts. The initial
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ker showed 40% sensitivity at 90% speciﬁcity, which is
very similar to the performance of CEA and better
than that of CA19-9. Our data did not provide sup-
port for a clear correlation between the serum levels of
HSP60 and the global staging of cancer, even though
HSP60 levels were signiﬁcantly higher in stage IV
patients than in other groups. This was somewhat
unexpected, because such a correlation has been shown
in tissue with the use of independent techniques
[16,17]. However, events observed in cancer tissue are
not always conﬁrmed in distal ﬂuids such as serum,
this being among the main difﬁculties of carrying out
marker discovery in tissue rather than directly in the
target ﬂuid [18]. In colonic tissue, the increase in
HSP60 expression is initiated early during carcinogene-
sis; it has even been reported to occur in preneoplastic
lesions [32]. This suggests that HSP60 could be of
interest for screening and early detection of CRC.
Unfortunately, the ELISA data that we generated
failed to support this hypothesis. In the veriﬁcation
cohort (cohort II), the difference in mean serum
HSP60 concentration between stage I patients and
healthy controls did not reach statistical signiﬁcance,
and the difference was barely signiﬁcant between
stage II patients and controls (P < 0.05). Serum
HSP60 levels were higher in stage IV patients than in
all other groups (Fig. 5B), reminiscent of CEA. As a
consequence, serum HSP60 seemed to be more useful
for prognosis and monitoring purposes than for
screening or early detection of CRC. However, a limi-
tation regarding this conclusion stems from the analyt-
ical limits of our HSP60 ELISA, which has a lower
quantiﬁcation limit of 0.3 ngÆmL
)1. Among CRC
patients, 38% had serum HSP60 levels below this
limit, suggesting that the marker may beneﬁt from an
assay method with increased analytical sensitivity that
is able to quantify in the dozens of pgÆmL
)1 range.
An increase in HSP60 expression as compared with
normal tissue has been shown for a variety of tumors,
including Hodgkin’s lymphoma, and prostate, ovarian
and breast adenocarcinomas (reviewed in [44]). At least
for some of these cancers, serum HSP60 levels might
be associated with the presence or progression of can-
cer, as we have shown for CRC. Furthermore, HSP60
is a key factor involved in inﬂammation, and serum
HSP60 levels might also be increased in patients with
inﬂammatory pathologies such as Crohn’s disease and
ulcerative colitis [45]. Further studies are needed to
determine the serum HSP60 levels in these populations,
to obtain a sound understanding of how serum HSP60
can be used to contribute to the prognosis or monitor-
ing of CRC patients.
Experimental procedures
Patients and specimens
Colonic adenocarcinoma and matching normal mucosa
were obtained from 23 patients who underwent surgical
resection. Normal mucosa was taken from the surgical mar-
gins, at least 10 cm away from the tumor, and was patho-
logically certiﬁed to be normal mucosa. Each patient gave
informed, written consent, and the sampling protocol was
in accordance with good clinical practice. All tissues were
collected in RPMI, immediately frozen in the pathology
laboratory after resection, and stored at )80  C until use.
Serum samples from 152 patients diagnosed with CRC
and 130 healthy volunteers were collected for the study.
CRC samples were obtained from academic hospitals in
Lyon, Dijon and Saint-Etienne (France), and control sam-
ples were obtained from blood donors at Etablissement
Franc ¸ ais du Sang, the French blood bank. Cohort I
included 40 CRC patients and 40 controls used for marker
qualiﬁcation, and cohort II included 112 CRC patients and
90 controls used for marker veriﬁcation.
2D-DIGE
Tissues were cut into small pieces, and were treated in a
Medicon (Dako, Hamburg, Germany) to generate a cell
suspension. Epithelial cells were separated from other cell
types present in tissue with the Dynabeads Epithelial Enrich
kit (Invitrogen, Cergy Pontoise, France), which targets
EpCam membrane antigen, and suspended in water
containing 0.9% NaCl and protease inhibitors (Roche
Diagnostics, Meylan, France). Cell lysis and protein extrac-
tion were carried out in lysis buffer (7 m urea, 2 m thiourea,
and 4% Chaps), with two cycles of sonication and freezing.
After centrifugation at 40 000 g for 30 min, the protein
content of the extract was determined with the Bio-Rad
Protein Assay kit (BioRad, Marnes la Coquette, France).
Protein labeling was carried out on 50 lg of each tumor
and matching normal mucosa extracts with Cy3 and Cy5
ﬂuorescent dyes. Caco-2 cell extract, used as an internal
standard, was labeled with Cy2 dye. According to the user
guide, a ratio of 400 pmol of ﬂuorescent dye per 50 lgo f
protein extract was used (GE Healthcare, Velizy Villacoub-
lay, France). The labeling reaction was performed at 4  C
for 30 min, and quenched with 1 lL of lysine (10 mm) for
10 min on ice, in the dark. For each patient, 50 lgo f
tumor and control extracts, labeled with different dyes, was
pooled with 50 lg of Cy2-labeled internal standard, and
was focused with immobilized pH gradient (IPG) strips
(Ready Strip pH 5–8, 17 cm; BioRad) on an IEF Cell
apparatus (BioRad). A dye-swap replicate was also used.
Following isoelectrofocalization, IPG strips were washed
with 50 mm Tris⁄HCl equilibration buffer containing 2%
dithiothreitol for 15 min, and then washed again with the
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SDS⁄PAGE was carried out for the second dimension,
using 7.7–16.5% gradient polyacrylamide gels, at 40 mA
per gel, for 5 h. Labeled proteins in each gel were visualized
with a ProXpress (Perkin Elmer, Courtaboeuf, France) ﬂu-
orescence scanner at 488⁄600 nm for Cy2, 532⁄580 nm for
Cy3, and 633⁄520 nm for Cy5.
Scanned gel images were analyzed with image mas-
ter 2d-platinium 6.0 (GE Healthcare). The best internal
standard image was used as the master reference. The pro-
tein spots on the other internal standard gel images were
matched with the master reference to ensure that the same
protein patterns were compared between gels. Spot volumes
measured on Cy3 and Cy5 gels were transformed in loga-
rithm base 2 and normalized by dividing each Cy3 or Cy5
spot volume by the corresponding Cy2 (internal standard)
spot volume. Abundance changes were calculated for each
paired tumor and control sample, and compared by the use
of Wilcoxon matched-pairs test.
MALDI-TOF MS
For each patient, a replicate 2D electrophoresis gel was run
with 1 mg of protein extract from cancer and adjacent nor-
mal tissue, stained with Simply Blue (Invitrogen), and then
matched with the 2D-DIGE gel maps. Protein spots were
excised from 2D electrophoresis gels and digested in-gel
with trypsin with the automated ProteineerSP and Protein-
eerDP robots (Bruker Daltonics, Wissembourg, France),
following the protocols of the manufacturer. Digests were
transferred automatically by thin-layer preparation on an
AnchorChip MALDI sample plate, with an a-cyano-4-hy-
droxycinnamic acid matrix. MS spectra were recorded in
the positive reﬂectron mode of an Ultraﬂex TOF⁄TOF
MALDI-TOF mass spectrometer (Bruker Daltonics). The
external calibration of MALDI mass spectra was carried
out with the singly charged monoisotopic peaks of Bruker’s
peptide mixture. To achieve mass accuracy, internal calibra-
tion was also performed with the peptides resulting from
the autolysis of trypsin. The peptide mass proﬁles obtained
by MALDI-TOF MS were analyzed with proteinscape 1.3
(Bruker Daltonics), using mascot 2.0 (MatrixScience, Lon-
don, UK) for peptide mass ﬁngerprinting. Observed peptide
masses were compared with the theoretical masses derived
from the sequences contained in the SWISS-PROT online
database. The search parameters used were as follows: carb-
amidomethylation for cysteines, oxidation, peptide mass tol-
erance of maximum 50 p.p.m. allowed, and a maximum of
one missed enzymatic cleavage. The species of origin was
restricted to human.
Western blot
Protein extraction from tissue samples was carried out as
for 2D-DIGE. SDS⁄PAGE was performed with 4–12% Bis-
Tris NuPage gels (Invitrogen); 10 lg of protein extract from
each patient was loaded per lane. Following electrophoretic
separation, proteins were transferred onto poly(vinylidene
diﬂuoride) membranes, stained with amidoblack, and incu-
bated for 1 h with antibodies diluted in blocking buffer (5%
nonfat dry milk, 15 mm Tris, pH 8, 140 mm NaCl, 0.5%
Tween-20). Antibodies directed against HSP60 (clo-
ne 11D5E10), GST-Pi (clone 2D1G1) and LEI (clo-
ne 21B10A5) were obtained in-house and used at a
concentration of 10 lgÆmL
)1. Antibodies against a-enolase
(sc-100812), PGAM1 (sc-130334), TCP1b (sc-28556) and
HSP90b (sc-69703) were from Santa-Cruz Biotechnology
(Heidelberg, Germany), antibody against a-tubulin (clo-
ne 17H11) was from Rockland Immunochemicals (Gilberts-
ville, PA, USA), and antibody against CK19 (61010) was
from Progen (Heidelberg, Germany). Commercial antibod-
ies were assayed at a dilution of 1 lgÆmL
)1. After three
washes with blocking buffer, membranes were incubated
with horseradish peroxidase-conjugated anti-(mouse IgG)
(Jackson ImmunoResearch, Newmarket, UK). Chemolumi-
nescent substrate was from Thermo Scientiﬁc (Super Signal
West Dura Extend Duration Substrate), and membranes
were scanned with a VersaDoc system (BioRad).
IHC
A small tissue microarray (TMA) was constructed with
archived formalin-ﬁxed, parafﬁn-embedded tissue blocks
from 20 colon cancer patients. For each patient, three
1.5-mm biopsy cores from the center of the tumor and
three from the invasion front were retrieved and inserted in
a recipient parafﬁn block. Similarly, three cores from
matching normal colon mucosa were collected and added
to the TMA block. Sections 4 lm thick were cut from the
TMA block and transferred to Superfrost slides (Menzel
Glaser, Braunschwrig, Germany), dewaxed with three baths
of toluene, and gradually rehydrated in alcohol⁄water baths
with decreasing alcohol content. Antigen retrieval was
carried out in 0.01 m (pH 6) citrate buffer for 30 min, at
98  C. Endogenous peroxidase activity was blocked with
3% hydrogen peroxide for 5 min. HSP60-speciﬁc mAbs
11D5E10 and 16F11D12, generated in-house, were diluted
to 5 lgÆmL
)1 with the background reducing dilution buffer
(Diagnostic BioSystems, Pleasanton, CA, USA), and were
incubated at room temperature for 1 h. Detection was
carried out according to the manufacturer’s instructions,
using the streptavidin–biotin-ampliﬁed Multilink kit
(Biogenex, Fremont, CA, USA); the chromogen amino-
3-ethyl-9-carbazole was incubated for 8 min. For nuclear
counterstaining, the slides were treated with hematoxylin
for 2 min.
TMA slides were digitized at · 20 magniﬁcation with the
Scanscope scanner (Aperio Technologies, Oxford, UK).
Virtual slides were examined by a pathologist on a com-
puter with imagescope (Aperio Technologies). For each
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sion front, the center of the tumor and normal mucosa was
evaluated. The scoring was based on staining intensity, and
results from triplicate cores were averaged. Imuunohisto-
chemical staining was graded as negative (0), weakly posi-
tive (1), moderately positive (2), and strongly positive (3).
Fluorescent ELISA
ELISA was performed on a VIDAS instrument, an auto-
mated immunoassay system (bioMe ´ rieux, Marcy l’e ´ toile,
France). The solid phase receptacle, which serves as both a
solid phase and a pipetting device, was coated with the cap-
ture mAb 11D5E10 at 30 lgÆmL
)1. The biotinylated detec-
tion antibody 16F11D12 was used at a concentration of
1 lgÆmL
)1. Buffers from a commercial VIDAS assay strip
(Cat. No. 30315, bioMe ´ rieux) were used as described in the
package insert, without additional changes. A hundred
microliters of each control, standard and serum sample was
directly added to well no. 2 of the VIDAS strip containing
the conjugate buffer. To lower the limit of detection, assays
were run with the long version of the assay protocol. Assay
of CEA and CA19-9 levels in serum samples was carried
out with commercially available VIDAS CEA (S) and
VIDAS CA19-9 kits (bioMe ´ rieux), following the protocol
provided by the manufacturer.
Method validation
Standard points were prepared with serial dilutions of a
recombinant HSP60 protein in a pool of control sera. To
generate the data that were used to ﬁt the master calibra-
tion curve, standard points were assayed in duplicate in ﬁve
consecutive runs. A four-parameter logistic function was
used to ﬁt these data. The accuracy of standard curves was
estimated by using r
2 for goodness of ﬁt and %RE for each
standard point. %RE was calculated as follows: [(back-cal-
culated value ) expected nominal value)⁄expected nominal
value] · 100%. Current guidelines recommend r
2 > 0.99
and RE £ 15% for standards other than at the lower limit
of quantiﬁcation [46].
Assay precision was assessed in a combined repeatability
and reproducibility experiment, with six sera that were
evenly distributed within the calibration range. Each sample
was tested in duplicate in each run; two runs per day and
per instrument were carried out on two instruments for
three consecutive days. A nested analysis of variance was
performed on interpolated concentrations.
To determine the LOB, a blank sample, chosen according
to the deﬁnition in the Clinical and Laboratory Standards
Institute EP17-A guideline, was assayed 42 times. The LOB
was deﬁned as the 95th percentile of the distribution of
blank doses interpolated from the standard curve. The
LOD was estimated with four serum samples with low
HSP60 concentration (LOB < concentration < 4 · LOB),
tested as four replicates, for 3 days. The standard deviation
(SD) of this dataset was calculated in terms of dose,
and the LOD was deﬁned as LOB + cSD, where
c = 1.645⁄(1 ) 1⁄4f), f being the degrees of freedom of
SD. The LLOQ was estimated with two of the samples used
for LOD assessment, with concentrations as close as possi-
ble to the LOD, and corresponds to the lowest reliable con-
centration that fulﬁls the accuracy expectation (RE £ 15%).
Statistical analyses
All statistical analyses were performed with graphpad
prism 5.0 or sas V9. A P-value of < 0.05 was considered
to be statistically signiﬁcant.
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